Therapeutic aspects of prostaglandins in the treatment of peptic ulcer disease
Author:
- 1 February 1986
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 31 (S2) , 42S-46S
Abstract
Studies of antisecretory compounds such as the H2-receptor antagonists have altered therapy and enhanced the understanding of peptic ulcer disease (PUD). While it is agreed that the dictum “no acid, no ulcer” is valid, acid hypersecretion does not appear to be the major determinant in a significant number of ulcer patients. More careful consideration of mucosal integrity in the pathogenesis of PUD is therefore necessary. A small but significant number of patients (5–15%) do not heal, despite the use of effective antiulcer drugs. Moreover, the posthealing recurrence rate may reach 75% after treatment is discontinued, and nearly one third of cigarette-smoking patients on maintenance therapy may suffer recurrences. Prostaglandins (PGs) are particularly important as potent antisecretory and effective antiulcer agents. In addition, recognition of their cytoprotective effects has stimulated research into the understanding and importance of mucosal protection and mucosal defense mechanisms. Animal studies show that PGs at nonantisecretory dosages prevent the development of gastric ulcers caused by virtually any insult. In humans, PGs prevent the mucosal damage caused by aspirin and ethanol. In some studies, the maintenance of normal mucosal integrity has been linked to normal mucosal production of PGs. Therefore, it is possible that exogenous PGs may be effective in patients whose ulcers do not heal with conventional therapy. They may reduce the recurrence of ulcers, particularly in those patients whose defect in mucosal integrity appars to be the major problem. Furthermore, in those patients subjected to the toxic effects of alcohol ingestion, nonsteroidal antiinflammatory drugs, antineoplastic drugs, and stress, exogenous PGs may prevent mucosal lesions. As such, PGs could be the ideal antiulcer drug.Keywords
This publication has 39 references indexed in Scilit:
- Prostaglandin E1 (Misoprostol) overcomes the adverse effect of chronic cigarette smoking on duodenal ulcer healingDigestive Diseases and Sciences, 1986
- Cimetidine, Cigarette Smoking, and Recurrence of Duodenal UlcerNew England Journal of Medicine, 1984
- Refractory duodenal ulcer.Gut, 1984
- Controlled Clinical Trial of Duodenal Ulcer Healing with Antacid TabletsScandinavian Journal of Gastroenterology, 1982
- Vasoconstriction with thromboxane A2 induces ulceration of the gastric mucosaNature, 1981
- Effects of E prostaglandins on canine gastric potential differenceDigestive Diseases and Sciences, 1978
- Stimulation of mucus and nonparietal cell secretion by the E2 prostaglandinsDigestive Diseases and Sciences, 1978
- Healing of Duodenal Ulcer with an Antacid RegimenNew England Journal of Medicine, 1977
- Double-blind clinical trial on gastroduodenal ulcer healing with prostaglandin E2 analogues.Gut, 1977
- Marked inhibition of gastric secretion by two prostaglandin analogs given orally to manLife Sciences, 1974